Photos: Courtesy of subjects

8 of 12
Behnam Badie, MD and Christine Brown, PhD
The Risk Takers
Glioblastoma is the most common and deadliest form of brain cancer in adults, with an average survival of less than 18 months. But that bleak prognosis may be changing, thanks to neurosurgeon Behnam Badie and cancer immunologist Christine Brown, both at City of Hope cancer center in California. They’re conducting human trials of a game-changing form of CAR T-cell therapy, using a technique in which genetically reprogrammed immune cells are injected directly into the brain to target and kill cancer cells. While the research is still in early stages, preliminary results are promising: Three months of treatment destroyed multiple tumors in one patient, who was able to go back to his job as a physician.